Table 3.
Clinical characteristics of patients at the diagnosis of NB with IM.
| Case | Symptoms of IM | Location of IM | Time interval from Dx to IM (months) | No. of brain lesions | Maximum diameter (cm) | Edema/enhancement | LP after IM | Treatment after IM | NIAT | Concomitant extra-CNS disease at the time of IM | NSE (ng/ml) at IM | LDH (U/l) at BM | SF (ng/ml) at IM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Skull mass | Skull; DM; scalp | 0 | 8 | 9.2*4.8 | Y/Y | N | Chemotherapy | Y | Liver; abdominal skin; lymphonodus | 188.3 | 488.9 | 193 |
| 2 | None | PB/Lt; subcutaneous soft tissue | 15 | 1 | 3.7*4.0*2.2 | N/Y | N | Chemotherapy | N | Bone marrow; lymphonodus | 53.31 | 244.7 | 115.1 |
| 3 | Headache | DM of FB (middle and Rt) | 0 | 2 | 5.2*0.7 | N/N | N | Chemotherapy +Surgery | Y | Bone; bone marrow; lymphonodus | 33.96 | 256 | 1,088 |
| 4 | None | FB/Bil; PB/Rt | 2 | 3 | 4.1*1.2 | N/N | N | Chemotherapy +Surgery | N | Bone marrow | 32.8 | 264 | 295.5 |
| 5 | Skull mass | Parieto-occipital juncture; nasal root | 28 | 2 | 3.2*1.9 | N/Y | N | Chemotherapy | N | Lung; pleura; canalis vertebralis | 225.6 | 594 | 1,419 |
| 6 | Skull mass | Parieto-occipital juncture/Bil; PL/Rt; DM of PL/Rt | 18 | 4 | 5.1*0.9*4.9 | Y/Y | Y | Chemotherapy | N | Bone | 66.5 | 298.2 | 342 |
| 7 | Skull mass | FTB/Lt and scalp/Lt | 2 | 1 | 3.0*2.0*1.5 | Y/N | N | Chemotherapy | N | Bone marrow | 239.4 | 871.2 | 1,139 |
| 8 | Seizure | DM of frontal, parietal, and temporal bone (Bil) | 18 | 6 | 8.1*1.5*5.0 | Y/Y | N | Chemotherapy | N | Bone marrow; lymphonodus. | 192 | 611.2 | 1,325 |
| 9 | Orbital ecchymosis | DM of PB/Bi; FB/Lt; temporal pole/Rt | 0 | 8 | 10.1*1.7*5.4 | Y/Y | N | Chemotherapy | Y | Bone marrow; skull | 193.4 | 796.6 | 515 |
| 10 | None | PB/Bil | 0 | 2 | 1.7*1.3*1.5 | N/N | N | Chemotherapy + Surgery +SCT | Y | None | NA | NA | NA |
| 11 | Skull mass | Parietal scalp and bone/Rt and PL/Rt | 28 | 1 | 5.7*9.7*5.8 | Y/Y | N | Chemotherapy | N | Bone marrow; lymphonodus | 136.7 | 366.8 | 230.6 |
| 12 | Skull mass; proptosis | FB/Bil; skull base | 0 | 3 | 4.6*0.7 | Y/Y | N | Chemotherapy | Y | None | 370 | 890 | 1,150 |
| 13 | Blindness | Parieto-occipital meninges/Rt; occipitotemporal meninges/Lt | 36 | 3 | 3.6*0.9*3.0 | Y/N | N | Chemotherapy | Y | Bone marrow; lymphonodus | 370 | 1003.2 | 1,214 |
| 14 | Skull mass | PL/Lt; frontal occipital meninges; orbital bone/Bil | 14 | 6 | 4.5*3.0*3.8 | Y/N | N | Chemotherapy | N | Bone; bone marrow | 176 | 809 | 760 |
| 15 | Skull mass | Temporal meninges/Lt; orbital bone/Lt; basicranial bone | 0 | 3 | 6.2*0.8*4.8 | Y/Y | Y | Chemotherapy +Surgery + SCT | Y | Bone; bone marrow; lymphonodus | 15 | 256.5 | 720.5 |
| 16 | Eyelid ecchymosis | DM of frontoparietal/Bil; DM of skull base; sellar region and clival bone | 2 | 6 | 6.2*0.8*4.8 | Y/Y | N | Chemotherapy | Y | Liver; pleura; bone marrow; lymphonodus | 370 | 883.1 | 416.4 |
| 17 | Skull mass; headache | Occipitotemporal meninges/Lt | 38 | 2 | 4.5*3.0*3.8 | Y/Y | Y | Chemotherapy+ II | Y | Skull; spine; ribs/Bil; pelvis; humerus/Bil | 370 | 769.4 | 773.8 |
| 18 | None | Occipitotemporal meninges/Lt; TB; OB | 55 | 4 | 3.6*1.0*3.7 | N/N | N | Chemotherapy | N | Bone; bone marrow | 178.5 | 735 | 233.9 |
| 19 | Skull mass | DM (FB/Bil+TB/Lt); orbital bone/Bil | 20 | 10 | 3.4*1.8*2.0 | Y/Y | N | Chemotherapy | Y | Skull | 25.8 | 225.3 | 195.5 |
| 20 | Skull mass; proptosis | Frontotemporal bone; orbital bone/Rt | 0 | 9 | 4.5*3.0*2.1 | Y/N | N | Chemotherapy | N | Skull; spine; orbital bone; femur/Bil; bone marrow; lymphonodus | 370 | 1,120 | 2,000 |
| 21 | Headache, vomiting, drowsiness | TL/Lt; + cerebellum/Lt | 1 | 4 | 7.64*3.35*2.80 | Y/Y | N | Chemotherapy | N | Bone; bone marrow | 28.37 | 1,083 | 284 |
| 22 | Seizure | MCP/Lt; Falx cerebri | 22 | 1 | 1.2*1.1 | Y/Y | N | Chemotherapy | N | Bone; liver | 19.93 | 331.1 | 2,000 |
Bil, bilateral; DM, dura mater; II, intrathecal injection; IM, intracranial metastasis; FL, frontal lobe; FTB, frontotemporal bone; FB, frontal bone; Lt, left; Rt, MCP, middle cerebellar peduncle; NIAT, neurologic improvement after treatment; OB, occipital bone; OL, occipital lobe; PB, parietal bone; PL, parietal lobe; TB, temporal bone; TL, temporal lobe; right; SF, serum ferritin.